Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Larimar Therapeutics (NASDAQ:LRMR) has received a consensus "Moderate Buy" rating from analysts, with an average one-year target price of $16.50. Institutional investors hold a significant portion of the stock, and the company is currently engaged in Phase 2 clinical trials for its lead product candidate, CTI-1601, targeting Friedreich's ataxia. The article also provides recent analyst actions and details on institutional investor activity.
We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully
Larimar Therapeutics (NASDAQ:LRMR) is an early-stage company with no revenue, burning through $97 million in the last year, giving it a cash runway of about 22 months as of September 2025. While the cash runway is not immediately alarming, the company's cash burn increased significantly by 65% in the last year, suggesting a need for careful business growth and potential future share dilution if more capital is needed. Shareholders should monitor these trends.
AIGH Capital Management LLC Takes $3.23 Million Position in Larimar Therapeutics, Inc. $LRMR
AIGH Capital Management LLC has acquired a new position in Larimar Therapeutics, Inc., purchasing 1,000,000 shares valued at approximately $3.23 million. This investment represents about 0.9% of AIGH’s portfolio and 1.21% ownership of Larimar, a clinical-stage biotechnology company developing treatments for Friedreich's ataxia. Larimar Therapeutics currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $16.71, despite missing Q3 EPS estimates.
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Moderate Buy" from Analysts
Larimar Therapeutics, Inc. (NASDAQ:LRMR) has received an average rating of "Moderate Buy" from analysts, with ten firms covering the stock. The consensus price target is $16.71, while shares currently trade around $3.13. The company is developing CTI-1601 for Friedreich's ataxia and has significant institutional ownership, with some firms increasing their stakes despite a recent earnings miss.
Larimar Therapeutics (NASDAQ:LRMR) Raised to "Strong-Buy" at Leerink Partnrs
Leerink Partnrs has upgraded Larimar Therapeutics (NASDAQ:LRMR) to a "strong-buy" rating. Despite this upgrade, the consensus among analysts remains a "Moderate Buy" with an average price target of $16.71, significantly higher than its current trading price of around $3.37. Larimar Therapeutics, a clinical-stage biotech focused on rare diseases, recently reported a Q3 loss of $0.61 per share, missing estimates.
Short Interest in Larimar Therapeutics, Inc. (NASDAQ:LRMR) Decreases By 19.2%
Larimar Therapeutics, Inc. (NASDAQ:LRMR) saw a 19.2% decrease in short interest in December, bringing the total to 7,922,334 shares as of December 15th. This represents about 10% of the company's shares being short sold, with a days-to-cover ratio of 5.8. Despite a recent stock decline and missed earnings estimates, analysts maintain a "Moderate Buy" rating with an average target price of $16.71.
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Larimar Therapeutics announced that its management team will present and participate in investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation is scheduled for January 14, 2026, and a webcast link will be available for those wishing to attend virtually, with a replay accessible for 30 days afterward. Larimar Therapeutics, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases, with its lead compound, nomlabofusp, targeting Friedreich's ataxia.
Larimar Heads to JPMorgan as Rare Disease Program Draws Investor Attention
Larimar Therapeutics, Inc. (Nasdaq: LRMR) will present at the 44th Annual J.P. Morgan Healthcare Conference, a significant event for emerging biotech firms. The company plans to highlight its lead drug candidate, nomlabofusp, for Friedreich's ataxia, and its intracellular delivery platform for other rare diseases. This participation underscores the continued investor interest in rare disease drug development.
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Moderate Buy" by Analysts
Larimar Therapeutics (NASDAQ:LRMR) has received a consensus "Moderate Buy" rating from nine analysts, with an average 12-month price target of $16.71. The company recently missed quarterly EPS estimates, reporting ($0.61) against an expected ($0.39), and its stock trades near $4.00, up 9.6% on the reported day, with a market capitalization of approximately $331 million. Larimar is a clinical-stage biotech developing CTI-1601 for Friedreich's ataxia, and institutional investors hold about 91.9% of its stock.
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Larimar Therapeutics announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026. The presentation is scheduled for January 14, 2026, at 9:00 AM PST. A webcast link and replay will be available, and the company will also participate in 1x1 investor meetings to discuss its clinical-stage biotechnology and lead compound, nomlabofusp, for Friedreich's ataxia. Larimar Therapeutics focuses on developing treatments for complex rare diseases.
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced that its management team will present and participate in investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026. The presentation will occur on Wednesday, January 14, 2026, from 9:00 – 9:40 AM PST, with a webcast link available. A replay will be accessible for 30 days post-presentation on their website.
Larimar Therapeutics exchanges common stock for preferred shares in agreement with Blue Owl
Larimar Therapeutics (NASDAQ:LRMR) announced an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP. Blue Owl exchanged 2.5 million shares of common stock for 250,000 shares of newly designated Series A convertible preferred stock. The preferred shares have specific conversion terms, limited voting rights, and participate equally with common stockholders in liquidation.
Larimar Therapeutics exchanges common stock for preferred shares in agreement with Blue Owl
Larimar Therapeutics (NASDAQ:LRMR) announced an agreement with Blue Owl Healthcare Opportunities IV Public Investments LP, exchanging 2,500,000 shares of common stock for 250,000 shares of newly designated Series A convertible preferred stock. The preferred shares have specific conversion rights and limitations, including a beneficial ownership blocker. This exchange comes amidst recent analyst reports on Larimar's drug nomlabofusp, with some maintaining positive ratings despite safety concerns.
Larimar Therapeutics Executes Strategic Stock Exchange Agreement
Larimar Therapeutics executed an exchange agreement with Blue Owl Healthcare Opportunities IV Public Investments LP, swapping common stock for Series A convertible preferred stock. This strategic move aims to optimize the company's capital structure and ensure financial stability. An analyst maintains a Buy rating with a $21.00 price target, while TipRanks' AI Analyst, Spark, rates LRMR as Neutral due to its early-stage status, high R&D costs, and lack of consistent revenue.
Top 3 Health Care Stocks That May Rocket Higher In December
This article identifies three healthcare stocks—Larimar Therapeutics Inc (LRMR), Perrigo Company PLC (PRGO), and ORIC Pharmaceuticals Inc (ORIC)—that are currently oversold according to their Relative Strength Index (RSI) values below 30. Each company recently reported news that impacted its stock price, with Larimar and Perrigo experiencing losses or guidance cuts, while ORIC received an "Outperform" rating from Evercore ISI Group. The author suggests these oversold conditions may present a buying opportunity for investors.
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Larimar Therapeutics, Inc. (NASDAQ:LRMR) has received a "Moderate Buy" consensus recommendation from analysts, with eight out of nine rating it a "buy" and one a "sell." Despite several firms recently lowering their price targets, the average 12-month target price is $16.71. The clinical-stage biotech, whose lead candidate CTI-1601 is in a Phase 2 trial for Friedreich’s ataxia, reported a quarterly EPS miss and has significant institutional ownership.
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
Rosen Law Firm is investigating potential securities claims against Larimar Therapeutics, Inc. (NASDAQ: LRMR) following allegations of materially misleading business information. This investigation stems from a significant stock drop after seven anaphylaxis events were disclosed in a study for nomlabofusp, causing Larimar's stock to fall 33.66% on September 29, 2025. Investors who purchased Larimar Therapeutics securities are encouraged to contact the law firm to join the prospective class action and seek compensation for their losses.
Larimar Therapeutics, Inc. Updates on Nomlabofusp Development
Larimar Therapeutics, Inc. (LRMR) has provided updates on its nomlabofusp clinical program, indicating its potential as the first disease-modifying therapy for Friedreich’s Ataxia. The company reported that 100% of study participants achieved significant skin FXN levels by Day 180 and plans a BLA submission for nomlabofusp in Q2 2026. Larimar also highlighted FDA agreement on a new dosing regimen to mitigate anaphylaxis risk and projected a cash runway extending into Q4 2026.
Larimar Therapeutics Inc expected to post a loss of 40 cents a share - Earnings Preview
Larimar Therapeutics Inc (LRMR) is projected to report a loss of 40 cents per share with no change in quarterly revenue for the period ending September 30, 2025. Analysts currently rate the shares as a "strong buy," with a median 12-month price target of $18.00, significantly above its last closing price. The article also provides historical quarterly performance data for the company.
Larimar Therapeutics Reports Third Quarter 2025 Financial Results
Larimar Therapeutics announced its third quarter 2025 financial and operating results, highlighting positive long-term data from its open-label study for nomlabofusp in Friedreich's Ataxia, showing consistent improvement in key clinical measures and increased frataxin levels. The company is implementing a modified starting dose regimen for nomlabofusp to mitigate anaphylaxis risk, preparing for Phase 3 study initiation, and targeting a BLA submission in Q2 2026. Larimar reported $175.4 million in cash, cash equivalents, and marketable securities, providing a projected cash runway into Q4 2026.
Larimar Therapeutics Bets Big On Its Lead Drug Nomlabofusp
Larimar Therapeutics reported a substantial net loss in Q3 due to increased R&D spending on its lead drug, nomlabofusp, targeting FDA approval and a 2027 US launch. Despite current losses, analysts maintain a bullish outlook on the stock, citing progress toward a 2026 biologics application and significant upside potential. This situation highlights the high-risk, high-reward nature of biotech investments and the substantial costs involved in bringing new therapies to market.
|Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
|Larimar Therapeutics announced positive long-term data from its open-label study of nomlabofusp for Friedreich’s Ataxia, showing increased skin FXN levels and consistent directional improvement across key clinical outcomes. The company also provided updates on its development program, including a modified starting dose regimen due to anaphylaxis events and a targeted BLA submission in Q2 2026. These results suggest nomlabofusp has the potential to be a disease-modifying therapy for FA.
Rosen Law Firm Encourages Larimar Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – LRMR
The Rosen Law Firm has initiated an investigation into potential securities claims on behalf of investors in Larimar Therapeutics, Inc. (NASDAQ: LRMR) due to allegations of materially misleading business information. This investigation follows a significant stock drop after seven anaphylaxis events were disclosed in a study for Friedreich’s ataxia. Investors who purchased Larimar Therapeutics securities may be entitled to compensation through a class action lawsuit.
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - The Malaysian Reserve
The article announces an opportunity for investors in Larimar Therapeutics, Inc. (LRMR) to join a fraud investigation led by The Schall Law Firm. This investigation is being initiated on behalf of investors who have experienced losses with their investments in the company.
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR
DJS Law Group is investigating Larimar Therapeutics, Inc. (NASDAQ: LRMR) for potential securities fraud violations. The investigation stems from a significant drop in Larimar's share price following the announcement of an open-label study showing severe allergic reactions to its Friedreich's Ataxia treatment, despite the company portraying the results as positive. Shareholders who suffered losses are encouraged to contact DJS Law Group to discuss their rights.
Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR - MarketScreener
The DJS Law Group is investigating Larimar Therapeutics, Inc. (NASDAQ: LRMR) for potential securities law violations after its stock fell significantly. The investigation follows a study of its Friedreich's Ataxia treatment, Nomlabofusp, where multiple participants experienced severe allergic reactions, despite the company's portrayal of positive results. The law group is seeking shareholders who suffered losses to participate in the investigation.
LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - FinancialContent
The Schall Law Firm has initiated a fraud investigation into Larimar Therapeutics, Inc. (LRMR) following a significant stock drop. This comes after the company announced "positive" data from a study for Friedreich's Ataxia, but also disclosed severe allergic reactions in seven participants, causing its shares to fall over 33.6%. The firm is encouraging investors who suffered losses to contact them to discuss their legal rights.
FA drug boosts frataxin protein, improves heart function in mice - Friedreich's Ataxia News
A study showed that the investigational therapy nomlabofusp increased frataxin protein levels, improved heart function, and extended survival in Friedreich's ataxia (FA) mouse models. These preclinical findings are consistent with benefits observed in clinical trials of nomlabofusp in FA patients and support its potential as a treatment addressing frataxin deficiency. Larimar plans to launch a global Phase 3 clinical trial and seek regulatory approval in the U.S. next year.
Larimar Therapeutics, Inc. Securities Lawsuit Investigation - Claim Depot
Larimar Therapeutics, Inc. is facing a securities lawsuit investigation concerning potential misleading statements about the safety of its lead drug candidate, nomlabofusp, for Friedreich’s ataxia. Investors who purchased securities between December 2024 and September 2025 and incurred losses may be eligible to join the investigation and seek compensation. The probe focuses on whether the company accurately disclosed the drug's safety profile and the accumulating incidence of severe allergic reactions.
Larimar Therapeutics Reports Promising Clinical Data Update - TipRanks
Larimar Therapeutics announced updated clinical data for nomlabofusp, a therapy for Friedreich’s Ataxia, showing promising results in clinical outcomes and frataxin levels. Despite some anaphylaxis cases, the therapy was generally well tolerated, leading to a modified dosing regimen and plans for a Biologics License Application in Q2 2026. An analyst rated the LRMR stock as a Buy with an $18.00 price target, while TipRanks' AI Analyst rated it Neutral due to its early-stage biotech status and high R&D costs.
Larimar Therapeutics, Inc. Updates on Nomlabofusp Development - TradingView
Larimar Therapeutics, Inc. provided updates on its nomlabofusp clinical development program on October 14, 2025. The drug shows potential for Friedreich’s Ataxia, with 100% of study participants achieving significant skin FXN levels by Day 180. Larimar plans to submit a Biologics License Application in Q2 2026 and projects its cash runway to extend into Q4 2026.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
Pomerantz LLP is investigating potential securities fraud claims against Larimar Therapeutics, Inc. (NASDAQ: LRMR) on behalf of investors. This investigation follows a significant stock price drop after Larimar reported "positive" data from a study, yet also disclosed that seven participants experienced anaphylaxis or severe allergic reactions. Investors who suffered losses are encouraged to contact Pomerantz LLP for more information regarding a potential class action lawsuit.
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
Larimar Therapeutics announced positive long-term open-label study data for nomlabofusp in Friedreich’s ataxia, showing consistent directional improvements across key clinical outcomes and increased skin frataxin levels. The company plans a Biologics License Application (BLA) submission for accelerated approval in Q2 2026. While anaphylaxis was reported in some participants early in treatment, long-term dosing was generally well-tolerated, and a modified starting dose regimen has been agreed upon with the FDA.
100% of Friedreich's Ataxia Patients Hit Critical Protein Levels: Larimar's Drug Shows Disease-Modifying Potential
Larimar Therapeutics announced positive long-term open-label study data for nomlabofusp, its drug for Friedreich's ataxia. All 10 participants with 6-month data achieved skin frataxin levels over 50% of healthy volunteers, comparable to asymptomatic carriers. The study also showed consistent improvements across four clinical outcomes after one year, despite seven participants experiencing anaphylaxis within the first six weeks, prompting protocol modifications.
Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study
Larimar Therapeutics' stock plummeted in pre-market trading despite positive data from a study of its drug Nomlabofusp for Friedreich’s Ataxia. The stock's decline was triggered by the report of a high anaphylaxis rate in seven participants who were subsequently withdrawn. The company has since modified its starting dose regimen for the drug, with agreement from the U.S. FDA, and plans to submit an application for approval in Q2 2026.
Larimar Therapeutics to Host Conference Call on Nomlabofusp Clinical Development Program for Friedreich's Ataxia
Larimar Therapeutics, Inc. announced a conference call and webcast on September 29, 2025, to provide updates on their nomlabofusp clinical development program for Friedreich's ataxia. The company is advancing nomlabofusp and other potential treatments for rare diseases and detailed insider trading activity and analyst ratings for its stock, LRMR.
Rare Disease Biotech Larimar to Present Long-term Data for Breakthrough Friedreich's Ataxia Drug
Larimar Therapeutics, a clinical-stage biotech company (NASDAQ:LRMR), has scheduled a conference call and webcast for September 29, 2025, at 8:00 am EDT to discuss updates on their nomlabofusp clinical development program for Friedreich's ataxia. The presentation will include data from the ongoing long-term open-label study. Investors can access the webcast or join by phone, and an archived version will be available on the company's website.
Following a 31% decline over last year, recent gains may please Larimar Therapeutics, Inc. (NASDAQ:LRMR) hedge funds owners
Larimar Therapeutics, Inc. (NASDAQ:LRMR) experienced a 31% decline in its stock price over the last year, but a recent 13% gain offers a positive sign for hedge funds, which hold 36% of the company's shares. Institutional investors collectively own a significant stake, with the top four shareholders controlling 53% of the business. Insider ownership is also present, with insiders holding US$3.7 million worth of shares, suggesting some alignment of interests.
Larimar's Friedreich's Ataxia Drug Nears BLA Filing as FDA Provides Clear Path Forward
Larimar Therapeutics (Nasdaq: LRMR) reported Q2 2025 financial results, including a net loss of $26.2 million and a pro forma cash runway of $203.6 million into Q4 2026. The company is advancing its nomlabofusp program for Friedreich's ataxia, with plans to submit a Biologics License Application (BLA) for accelerated approval in Q2 2026 based on clear FDA guidance. Key upcoming catalysts include initial data from the 50 mg open-label study and adolescent PK run-in study in September 2025, and the initiation of global Phase 3 study patient recruitment later in 2025.
Mintz Advises on Larimar Therapeutics’ $69 Million Public Offering
Mintz advised the underwriters in connection with Larimar Therapeutics, Inc.'s $69 million public offering. The offering involved 21,562,500 shares of common stock at $3.20 per share. Leerink Partners LLC, Guggenheim Securities, LLC, Truist Securities, Inc., and William Blair & Company, L.L.C. served as joint book-running managers.
Larimar Therapeutics Closes $69 Million Public Offering of Common Stock to Support Development of Pipeline Candidates
Larimar Therapeutics, Inc. successfully closed a public offering, raising $69.0 million by selling 21,562,500 shares of common stock at $3.20 per share. The proceeds will fund the development of its lead candidate, nomlabofusp, other pipeline projects, and general corporate purposes. This financing included the full exercise of the underwriters' option for additional shares, indicating strong investor interest.
Larimar Prices $60 Mln Public Offering Of 18.75M Shares At $3.20 Each
Larimar Therapeutics has priced an underwritten public offering of 18.75 million shares at $3.20 per share, aiming to raise $60 million. The company also granted underwriters an option to purchase an additional 2.81 million shares. Proceeds will be used to advance nomlabofusp and other pipeline candidates, as well as for general corporate purposes.
Larimar Therapeutics, Inc. Announces Pricing of $60 Million Public Offering of Common Stock | LRMR Stock News
Larimar Therapeutics, Inc. announced the pricing of a public offering of 18,750,000 shares of common stock at $3.20 per share, aiming to raise $60 million. The proceeds will fund the development of nomlabofusp and other pipeline candidates, as well as general corporate purposes. The offering is expected to close around July 31, 2025, with an option for underwriters to purchase additional shares.
Larimar Therapeutics Announces Proposed Underwritten Public Offering
Larimar Therapeutics has announced an underwritten public offering of its common stock and pre-funded warrants, with an option for underwriters to purchase additional securities. The company plans to use the net proceeds to advance its pipeline candidates, including nomlabofusp, and for general corporate purposes. The offering is subject to market conditions and is being managed by Leerink Partners and Guggenheim Securities.
First Disease-Modifying Treatment for Friedreich's Ataxia Advances Toward FDA Accelerated Approval
Larimar Therapeutics has published nonclinical data supporting its drug nomlabofusp as a potential first-in-class disease-modifying treatment for Friedreich's ataxia. The research demonstrates the drug's mechanism of action and its ability to increase frataxin protein levels, with the FDA showing openness to using skin frataxin concentrations as a surrogate endpoint for accelerated approval. Larimar plans to submit a Biologics License Application (BLA) in Q2 2026, aiming for accelerated approval.
FDA provides path for accelerated approval of nomlabofusp for FA
The FDA has outlined an accelerated approval pathway for Larimar Therapeutics' nomlabofusp, a drug for Friedreich's ataxia (FA), which is designed to restore frataxin protein levels. This clarity on safety monitoring requirements has prompted Larimar to extend its BLA submission timeline to mid-2026 to gather sufficient safety data for both adults and children. The drug, which participates in the FDA's START pilot program, is undergoing open-label extension studies, with data on sustained frataxin increases and tolerability expected in September.
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
Larimar Therapeutics announced that it will host a conference call and webcast on Monday, June 23, 2025, at 8:00 am EDT to discuss regulatory updates for its nomlabofusp clinical development program for the treatment of Friedreich’s Ataxia. The company is a clinical-stage biotechnology company focused on rare diseases, with nomlabofusp as its lead compound.
Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight
The Friedreich's ataxia market is expected to expand rapidly from 2025 to 2034, driven by a robust drug pipeline including therapies like RT001, Vatiquinone, and Leriglitazone. The United States is projected to hold the largest market share due to increased awareness and diagnostic capabilities. Despite challenges like diagnostic delays and high R&D costs, the anticipated launch of new, more effective therapies, including those targeting the underlying pathology such as frataxin, is set to significantly transform the treatment landscape.
Larimar Therapeutics, Inc.’s (LRMR): Analysts See 957% Upside Potential
Analysts are projecting a 957% upside potential for Larimar Therapeutics, Inc. (LRMR) over the next 12 months, with a price target of $20.04. The biotechnology company is focused on developing treatments for rare genetic disorders, particularly Friedreich’s ataxia (FA) with its therapeutic candidate Nomlabofusp, and maintains a strong financial foundation with $157.5 million in cash as of Q1 2025. Despite a previous share price decline due to adverse events, experts remain optimistic about the company's innovative technologies and potential for growth.
Is Larimar Therapeutics (LRMR) the Best Multibagger Stock to Buy Heading into 2025?
This article evaluates Larimar Therapeutics (LRMR) as a potential multibagger stock for 2025, detailing its financial and operational updates, particularly focusing on its lead drug candidate, nomlabofusp, for Friedreich's ataxia. It discusses the market's broader economic context, including Fed rate cuts and post-election optimism, and provides Larimar's share performance, analyst ratings, and strategic plans for regulatory approval and market expansion.
